Galderma agrees $1.5 billion acquisition of ZO Skin Health to expand dermatological skincare portfolio
Galderma has agreed to acquire ZO Skin Health for an enterprise value of $1.5 billion, expanding its physician-dispensed dermatological skincare portfolio.
The all-cash agreement covers 100% of ZO Skin Health and will add the company's professional skincare products to Galderma's dermatology business alongside its existing Alastin brand.
The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and customary closing conditions, and is intended to strengthen Galderma's position in medical aesthetics and skincare.
Field | Content |
Article Type | Deals |
Companies | Galderma; ZO Skin Health |
Deal Type | Acquisition agreement |
Target Company | ZO Skin Health |
Acquirer | Galderma |
Enterprise Value | $1.5 billion |
Transaction Structure | All-cash acquisition of 100% of ZO Skin Health |
Sellers | Shareholders including Blackstone-managed funds and the Obagi family |
Transaction Status | Agreement signed; completion pending |
Expected Closing | Fourth quarter of 2026 or early 2027 |
Closing Conditions | Regulatory approvals and customary closing conditions |
Business Segment | Physician-dispensed skincare and medical aesthetics |
Existing Portfolio Fit | Complementary to Galderma's Alastin skincare business |
Geography | International dermatology and skincare markets |
What Happened | Galderma agreed to acquire ZO Skin Health in an all-cash transaction with an enterprise value of $1.5 billion. |
Why It Matters | The acquisition would significantly expand Galderma's professional skincare portfolio and deepen its position in physician-dispensed dermatological products. |
Strategic Rationale | Galderma aims to combine ZO Skin Health with its existing skincare capabilities to strengthen its presence in medical aesthetics and dermatology. |
Key Takeaway | Galderma's proposed $1.5 billion acquisition of ZO Skin Health remains subject to closing conditions. |
What to Watch | Regulatory approvals, transaction closing, brand integration and commercial performance following acquisition. |
Primary Source | Galderma announcement |
Relevant Date | 14 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments